Drugs /

dcc-3116

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the serine/threonine-protein kinase ULK 1 and 2, with potential antineoplastic activity. Upon oral administration, ULK1/2 inhibitor DCC-3116 targets and binds to ULK1/2. This inhibits cancer autophagy, which mutant RAS cancer cells use for their survival, and results in tumor cell death. ULK1/2 mediates the autophagocytotic process and is often upregulated in cancers, especially in mutant RAS cancers. Autophagy plays a key role in a tumor cell proliferation and survival, and mediates tumor cell resistance.

Clinical Trials

View Clinical Trials for dcc-3116

Dcc-3116 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dcc-3116, 1 is phase 1 (1 open).

ARAF Mutation, BRAF Mutation, and HRAS Mutation are the most frequent biomarker inclusion criteria for dcc-3116 clinical trials.

Colorectal carcinoma, malignant solid tumor, and melanoma are the most common diseases being investigated in dcc-3116 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dcc-3116
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dcc-3116 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ulk1/2 inhibitor dcc-3116, dcc3116, dcc 3116
Drug Target(s) [2]:
ULK1, ULK2
NCIT ID [1]:
C180331

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.